UBE2Q2P2: A Drug Target / Disease Biomarker (G100134869)

Target Name: UBE2Q2P2

NCBI ID: G100134869

UBE2Q2P2

Other Name(s): UBE2QP2 | UBE2Q2 pseudogene 2 | UBE2Q2P3

UBE2Q2P2: A Drug Target / Disease Biomarker

UBE2Q2P2, also known as UBE2A, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and lungs. It is a member of the UBE2 family of proteins, which are known for their role in cell signaling and inflammation. UBE2Q2P2 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The UBE2 family of proteins was first identified in the late 1990s based on its ability to interact with the protein p120GAP. This interaction led to the conclusion that UBE2 proteins might be involved in intracellular signaling pathways that regulate cell growth, apoptosis, and inflammation. Since then, several studies have confirmed this involvement and have led to the identification of multiple UBE2 family members, including UBE2Q2P2.

UBE2Q2P2 is a 21-kDa protein that is expressed in various tissues, including the brain, heart, and lungs. It is a member of the UBE2 family of proteins, which are known for their role in cell signaling and inflammation. The UBE2 family includes several isoforms, including UBE2A, UBE2B, UBE2C, and UBE2D, which differ in their size and/or localization.

UBE2Q2P2 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the main reasons for its potential as a drug target is its involvement in cell signaling pathways that are relevant to many diseases, including cancer.

For example, UBE2Q2P2 has been shown to be involved in the regulation of cell growth, apoptosis, and angiogenesis, which are all processes that are disrupted in many types of cancer. Additionally, UBE2Q2P2 has been shown to play a role in the regulation of inflammation, which is a crucial aspect of cancer progression and the development of many types of autoimmune disorders.

Another potential reason for UBE2Q2P2's potential as a drug target is its localization to various tissues and organs, including the brain, heart, and lungs. This localization suggests that UBE2Q2P2 may be involved in the regulation of important processes that are specific to these tissues, such as cell survival and function.

In addition to its potential as a drug target, UBE2Q2P2 has also been identified as a potential biomarker for several diseases, including cancer. This is because its expression has been shown to be associated with the development and progression of many types of cancer, including breast, ovarian, and colorectal cancers.

The identification of UBE2Q2P2 as a potential drug target or biomarker has important implications for the development of new treatments for a variety of diseases. By targeting UBE2Q2P2 with small molecules or other therapeutic agents, researchers may be able to inhibit its role in cell signaling pathways that are relevant to many diseases, including cancer and neurodegenerative diseases.

In conclusion, UBE2Q2P2 is a protein that has been identified as a potential drug target or biomarker for various diseases. Its involvement in cell signaling pathways that are relevant to many diseases, including cancer and neurodegenerative diseases, makes it an attractive target for small molecules and other therapeutic agents. Further research is needed to fully understand the role of UBE2Q2P2 in disease and to develop effective treatments.

Protein Name: UBE2Q2 Pseudogene 2

The "UBE2Q2P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2Q2P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets